191 related articles for article (PubMed ID: 21258400)
1. ATR mediates cisplatin resistance in a p53 genotype-specific manner.
Sangster-Guity N; Conrad BH; Papadopoulos N; Bunz F
Oncogene; 2011 Jun; 30(22):2526-33. PubMed ID: 21258400
[TBL] [Abstract][Full Text] [Related]
2. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
Pabla N; Huang S; Mi QS; Daniel R; Dong Z
J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
[TBL] [Abstract][Full Text] [Related]
3. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
Gomes LR; Rocha CRR; Martins DJ; Fiore APZP; Kinker GS; Bruni-Cardoso A; Menck CFM
Cell Death Dis; 2019 Jun; 10(6):459. PubMed ID: 31189884
[TBL] [Abstract][Full Text] [Related]
4. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
Peasland A; Wang LZ; Rowling E; Kyle S; Chen T; Hopkins A; Cliby WA; Sarkaria J; Beale G; Edmondson RJ; Curtin NJ
Br J Cancer; 2011 Jul; 105(3):372-81. PubMed ID: 21730979
[TBL] [Abstract][Full Text] [Related]
5. Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin.
Lewis KA; Lilly KK; Reynolds EA; Sullivan WP; Kaufmann SH; Cliby WA
Mol Cancer Ther; 2009 Apr; 8(4):855-63. PubMed ID: 19372558
[TBL] [Abstract][Full Text] [Related]
6. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.
Reaper PM; Griffiths MR; Long JM; Charrier JD; Maccormick S; Charlton PA; Golec JM; Pollard JR
Nat Chem Biol; 2011 Apr; 7(7):428-30. PubMed ID: 21490603
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53.
Kim HS; Hwang JT; Yun H; Chi SG; Lee SJ; Kang I; Yoon KS; Choe WJ; Kim SS; Ha J
J Biol Chem; 2008 Feb; 283(7):3731-42. PubMed ID: 18079115
[TBL] [Abstract][Full Text] [Related]
8. Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
Sultana R; Abdel-Fatah T; Perry C; Moseley P; Albarakti N; Mohan V; Seedhouse C; Chan S; Madhusudan S
PLoS One; 2013; 8(2):e57098. PubMed ID: 23451157
[TBL] [Abstract][Full Text] [Related]
9. hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis.
Pabla N; Ma Z; McIlhatton MA; Fishel R; Dong Z
J Biol Chem; 2011 Mar; 286(12):10411-8. PubMed ID: 21285353
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin.
Yazlovitskaya EM; Persons DL
Anticancer Res; 2003; 23(3B):2275-9. PubMed ID: 12894503
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ATR-dependent signaling by protoapigenone and its derivative sensitizes cancer cells to interstrand cross-link-generating agents in vitro and in vivo.
Wang HC; Lee AY; Chou WC; Wu CC; Tseng CN; Liu KY; Lin WL; Chang FR; Chuang DW; Hunyadi A; Wu YC
Mol Cancer Ther; 2012 Jul; 11(7):1443-53. PubMed ID: 22532598
[TBL] [Abstract][Full Text] [Related]
12. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
13. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
15. Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival.
Wilsker D; Bunz F
Mol Cancer Ther; 2007 Apr; 6(4):1406-13. PubMed ID: 17431119
[TBL] [Abstract][Full Text] [Related]
16. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
Mohni KN; Thompson PS; Luzwick JW; Glick GG; Pendleton CS; Lehmann BD; Pietenpol JA; Cortez D
PLoS One; 2015; 10(5):e0125482. PubMed ID: 25965342
[TBL] [Abstract][Full Text] [Related]
17. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
Zheng H; Shao F; Martin S; Xu X; Deng CX
Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
[TBL] [Abstract][Full Text] [Related]
18. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo.
Ren X; Liu H; Zhang M; Wang M; Ma S
Mol Med Rep; 2016 Sep; 14(3):2431-8. PubMed ID: 27484725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
